C13 isotope labeling internal standard substance of MDMA and metabolite thereof, preparation method and application
By preparing carbon-13 labeled MDMA and its metabolites as internal standards, the problem of detection inaccuracy caused by the large structural difference between the internal standard and the target analyte in the prior art has been solved, and high sensitivity and high accuracy of MDMA and its metabolites detection have been achieved, especially for trace analysis in wastewater.
Patent Information
- Application Number
- CN202511046466.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-29
- Publication Date
- 2025-11-14
AI Technical Summary
In existing technologies, the detection methods for MDMA and its metabolites suffer from insufficient isotope dilution due to the large differences in molecular structure between the internal standard and the target analyte. This makes it difficult to achieve stable quantification in complex biological matrices, affecting the accuracy and reliability of the detection, especially in trace analysis in wastewater.
Using carbon-13 labeled MDMA and its metabolite internal standards, azacyclopropane intermediates were constructed through a reductive cyclization reaction to ensure that the internal standards and target analytes had completely matched chemical properties, chromatographic retention times, and fragment ion spectra. Liquid chromatography-mass spectrometry was used for detection to achieve nearly identical ionization efficiencies and chromatographic behavior between the internal standards and target analytes.
It improves the sensitivity and accuracy of detection, with a detection limit of 0.1 pg, a quantitation limit of ≤0.3 pg, a retention time consistency rate between the internal standard and the target analyte of less than 0.1%, and a spike recovery rate of 90-110%, significantly enhancing the reliability of detection and the traceability of judicial evidence.
Smart Images

Figure CN120943810A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of compound detection technology, and in particular to carbon-13 isotope labeled internal standards of MDMA and its metabolites, their preparation methods, and applications. Background Technology
[0002] In recent years, the concealment and diversity of psychoactive substance abuse have increased significantly, placing higher demands on precise detection technologies. Especially in the trace analysis of new drugs such as 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxymethamphetamine (MDA), matrix effects and insufficient internal standard matching have become core bottlenecks restricting detection accuracy. The current mainstream detection method is liquid chromatography-tandem mass spectrometry (LC-MS / MS), which relies on internal standards to correct for the extraction efficiency and ionization interference of the target analyte. However, existing internal standards often use chemically similar compounds (such as D3-MDMA or D5-diazepam), whose molecular structures differ significantly from the target analyte. This results in insufficient isotope dilution effects, making it difficult to completely offset interference from complex biological matrices (such as sewage and blood), thus affecting the reliability of quantitative results.
[0003] Isotope dilution mass spectrometry (IDMS), with its ultra-high sensitivity and resistance to matrix interference, has become the gold standard for the detection of trace psychoactive substances. This method uses isotope-labeled internal standards, whose physicochemical properties must be highly similar to those of the target analyte, differing only in molecular weight. In mass spectrometry, the internal standard and the target analyte have nearly identical ionization efficiencies and chromatographic behaviors, especially in retention time, which allows for real-time correction of pretreatment losses and instrument fluctuations, significantly improving detection accuracy. Studies have shown that structural homology between the internal standard and the target analyte is key to reducing matrix effects; however, current MDMA / MDA detection lacks high-quality, dedicated isotope internal standards, necessitating the development of structurally matched labeled compounds.
[0004] Wastewater, as a biological sample, has irreplaceable advantages in drug control practice: it can trace drug exposure history up to 6 months, providing objective evidence for determining drug addiction, evaluating the effectiveness of community-based drug rehabilitation, and monitoring relapse. However, the concentration of target substances in wastewater is extremely low (usually at the pg level), and there are interfering factors such as pigment binding and exogenous contamination, placing stringent requirements on the sensitivity and specificity of analytical methods. Existing technologies, due to insufficient internal standard compatibility, struggle to achieve stable quantification of MDMA / MDA in wastewater matrices, thus limiting the scientific rigor and legal validity of drug control forensic identification. Summary of the Invention
[0005] The main objective of this invention is to address the above-mentioned problems by providing a carbon-13 isotope-labeled internal standard for MDMA and its metabolites, its preparation method, and its application.
[0006] To achieve the above objectives, a first aspect of the present invention provides a carbon-13 isotope-labeled internal standard for MDMA and its metabolites, characterized in that the chemical structural formula of the internal standard is shown below:
[0007]
[0008] Where R is H or methyl.
[0009] A second aspect of the present invention provides a method for preparing an MDA carbon-13 isotope-labeled internal standard, characterized in that the preparation method includes the following steps:
[0010] (1) 13 C-C3-alanine is generated under transition metal catalysis. 13 C-C3-azacyclopropane;
[0011] (2) 13 C-C3-azacyclopropane reacts with a 3,4-methylenedioxyphenyl nucleophile to generate a carbon-13 isotopically labeled internal standard for MDA. 13 C-C3-3,4-methylenedioxyphenylamine.
[0012] Preferably, in step (1), the transition metal catalyst is Ir(acac)(CO)2;
[0013] In step (2), the reaction catalyst is CuBr or CuI; the reaction is stirred at temperature t2 for 2 hours, and then heated to room temperature t3 for 2 hours. t2 is -35℃ to 25℃, t3 is 0℃ to 25℃, and T2 is 1 to 4 hours.
[0014] A third aspect of the present invention provides a method for preparing an MDMA carbon-13 isotope-labeled internal standard, characterized in that the preparation method includes the following steps:
[0015] Internal standard labeled with MDA carbon-13 isotope 13 C-C3-3,4-methylenedioxyphenylamine is methylated to generate an MDMA carbon-13 isotope-labeled internal standard. 13 C-C3-3,4-Methylenedioxymethylamphetamine, MDA carbon-13 isotope labeled internal standard 13 C-C3-3,4-methylenedioxyphenylpropanamine was prepared using the method described above.
[0016] The fourth aspect of the invention provides the use of the carbon-13 isotope-labeled internal standard of the MDMA and its metabolites, or the carbon-13 isotope-labeled internal standard of MDA prepared by the preparation method, in detecting the MDA content in wastewater.
[0017] The fifth aspect of the invention provides the use of the carbon-13 isotope-labeled internal standard of the MDMA and its metabolites, or the carbon-13 isotope-labeled internal standard of MDMA prepared by the preparation method, in detecting the MDMA content in wastewater.
[0018] In the above-mentioned applications, the method for detecting the content of MDMA and its metabolites in biological samples or sewage using the carbon-13 isotope-labeled internal standard includes the following steps:
[0019] (1) Set the detection conditions for liquid chromatography-mass spectrometry;
[0020] (2) Construction of the standard curve: Different proportions of MDMA were added to the negative sample corresponding to the test sample. 13 C-C3-MDMA, MDA and 13 C-C3-MDA standard solution, after undergoing the same pretreatment steps as the test sample, was analyzed by LC-MS / MS to differentiate MDMA and... 13 C-C3-MDMA, MDA and 13 A standard curve was plotted using the peak area ratio and concentration of C-C3-MDA;
[0021] (3) Pretreatment and determination of the sample to be tested: The carbon-13 isotope labeled internal standard is added to the sample to be tested. After the same pretreatment steps as those used when plotting the standard curve, the sample is detected by LC-MS / MS to obtain the quantitative parameters of the sample and the internal standard. The content of the sample to be tested can be calculated by using the formula of the internal standard method standard curve.
[0022] Preferably, in step (1), the mobile phase for liquid chromatography-mass spectrometry detection is: A: acetonitrile (0.01% formic acid), B: water (0.01% formic acid, 5% ammonium formate), gradient: 1 min 10% A, 2 min 50% A, 4 min 90% A, 6 min 95% A; chromatographic column: Poroshell 120 PFP 3.0x100mm 1.9um; column temperature: 30℃; flow rate: 0.5mL / min; injection volume: 5μL; ion source: electrospray ion source, positive mode (ESI+); spray voltage 3500V; ion source temperature: 340℃; collision gas: nitrogen.
[0023] Preferably, in step (2), the mass concentration of the internal standard in the mixed standard solution is 0.1%-99.9%.
[0024] Preferably, in step (2), the mass concentration of the internal standard in the sample to be tested is 0.1%-99.9%.
[0025] Preferably, in step (3), the formula for calculating the internal standard method is: X = (Y - b0) / b1;
[0026] Where X is the concentration of the sample to be tested, Y is the peak area obtained by liquid chromatography-mass spectrometry, b0 is the intercept of the standard curve, and b1 is the slope of the standard curve.
[0027] Preferably, the mass content of the psychoactive substance MDMA and its metabolites in the biological sample or the wastewater is 10. -9 %-10%.
[0028] The present invention relates to a carbon-13 isotope-labeled internal standard for MDMA and its metabolites, its preparation method, and its application. The method utilizes carbon-13 labeled amino acids as the carbon-13 source, constructing azacyclopropane as a key intermediate via a reductive cyclization reaction. This intermediate requires no purification and can be directly used in subsequent reactions. Amphetamine structure is directly constructed through ring-opening reaction with organometallic reagents. The carbon-13 labeling is located at key sites on the benzene ring and alkyl chain, ensuring complete matching with the chemical properties, chromatographic retention time, and fragment ion spectra of natural MDMA / MDA. Its retention time is closer to the target analyte than that of deuterated products, exhibiting superior consistency. Carbon-13 exhibits no isotope exchange effect, which is superior to the hydrogen-deuterium exchange that may occur during long-term storage or pretreatment of deuterated internal standards. In an alkaline environment, its recovery rate is closer to 100%.
[0029] The carbon-13 isotope-labeled internal standard of MDMA and its metabolites of the present invention can be applied to IDMS, and can achieve:
[0030] Improved sensitivity: Limit of detection (LOD) reaches 0.1 pg (wastewater matrix), limit of quantitation (LOQ) ≤ 0.3 pg;
[0031] Improved consistency: The consistency rate between the retention times of the internal standard and the target analyte was reduced to less than 0.1%;
[0032] Accuracy optimization: Spike recovery rate (E%) 90-110%, significantly better than existing alternative internal standards (90-220%);
[0033] Strengthening the validity of judicial evidence: Providing traceable data support that complies with ISO / IEC 17025 standards for drug enforcement and the construction of court evidence chains.
[0034] This invention fills the technological gap of dedicated isotope internal standards for MDMA / MDA. Through the precise design and application of carbon-13 labeled standard materials, it promotes the development of psychoactive substance detection towards higher sensitivity, lower error, and stronger judicial credibility, which has significant social value for public safety and health management. Attached Figure Description
[0035] Figure 1 In Example 1 13 C-C3-MDMA high-resolution mass spectrum.
[0036] Figure 2 In Example 1 13 C-C3-MDMA 1 H-NMR spectrum.
[0037] Figure 3 In Example 1 13 C-C3-MDMA 13 C-NMR spectrum.
[0038] Figure 4 In Example 2 13 C-C3-MDA high-resolution mass spectrum.
[0039] Figure 5 In Example 2 13 C-C3-MDA 1 H-NMR spectrum.
[0040] Figure 6 In Example 2 13 C-C3-MDA 13 C-NMR spectrum.
[0041] Figure 7 This is the standard curve of wastewater MDMA in Example 3.
[0042] Figure 8 This is the standard curve of wastewater MDA in Example 3.
[0043] Figure 9 Wastewater in Example 3 13 C-C3-MDA sample detection chromatogram Figure 1 .
[0044] Figure 10 Wastewater in Example 3 13 C-C3-MDA sample detection chromatogram Figure 2 .
[0045] Figure 11 Chromatography for the detection of D5-MDMA in wastewater samples in Example 4 Figure 1 .
[0046] Figure 12 Chromatographic detection of wastewater D5-MDMA sample in Example 4 Figure 2 . Detailed Implementation
[0047] To provide a clearer understanding of the technical content of this invention, the following embodiments are provided in detail. However, it is important to note that these descriptions are merely for further illustrating the features and advantages of this invention, and not for limiting the scope of the claims.
[0048] In the description of this invention, "matrix effect" refers to the influence and interference of substances in the sample other than the analyte MDMA and its metabolites on the analytical process and detection results.
[0049] In the description of this invention, the mass concentration of MDMA and its metabolites in wastewater is 10. -9 %-10%.
[0050] The isotope-labeled internal standard provided by this invention 13 C-C3-3,4-methylenedioxyamphetamine and 13 The chemical structural formula of C-C3-3,4-methylenedioxymethylamphetamine is as follows:
[0051]
[0052] The present invention will be further described below with reference to specific embodiments.
[0053] Example 1
[0054] Preparation by reduction-ring-opening reaction 13 C-C3-3,4-methylenedioxyamphetamine ( 13 Preparation method of C-C3-MDA.
[0055] The carbon-13 labeled amino acid (DL-alanine-) was synthesized under nitrogen protection. 13 C3 (CAS: 144476-54-0, 10 mmol) and catalyst C1 (14023-80-4) were dissolved in 50 mL of anhydrous and oxygen-free solvent S1, and hydrogen was introduced at 0 °C P1. After the reaction was complete, a 30% sulfuric acid-methanol solution was added, and the reaction was carried out at a specified temperature t1 at room temperature T1. After diluting the mixture with diethyl ether, the layers separated, the organic layer was dried with anhydrous magnesium sulfate, filtered, and concentrated. Under nitrogen protection, 5 mmol of catalyst C2 and 60 mmol of 1M solution of 3,4-methylenedioxyphenyl magnesium bromide (60 mL) were added to a two-necked flask in anhydrous tetrahydrofuran. The reaction mixture was cooled to t2 and stirred for about 30 minutes. A C13-labeled azacyclopropane solution dissolved in 160 mL of anhydrous tetrahydrofuran was slowly added dropwise using a syringe. Stirring was continued at temperature t2 for 2 hours, and the temperature was raised to t3 at room temperature for T2 hours. The reaction was quenched with ammonium chloride aqueous solution, and the mixture was extracted three times (40 mL each) with ethyl acetate (EtOAc). The combined organic phases were washed with saturated sodium chloride solution, and the organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated. The crude product was purified by rapid alkaline alumina column chromatography (n-hexane / ethyl acetate, 80:20) to obtain the final product. 13 C-C3-MDMA), a colorless liquid, yields are shown in Table 1.
[0056] 1H NMR(600MHz,cd3od)δ6.81–6.74(m,2H),6.76-6.66(m,1H),5.93(s,2H),3.61-3.56(m,0.5H),3.38–3.31(m,0.5H),3.00-2.94(m,0 .5H),2.87-2.81(m,0.5H),2.79-2.73(m,0.5H),2.65-2.59(m,0.5H),1.36(dt,J=6.6,4.4Hz,1.5H),1.14(dt,J=6.6,4.4Hz,1.5H).
[0057] 13 C NMR(151MHz,cd3od)δ149.64(d),148.44(s),131.09(s),130.80(s),123. 61(t),110.44(q),109.57(d),102.51(s),50.42(q),49.04(h),18.34(d).
[0058] HR-MS (ESI / TOF) m / z:Calcd.for C713C3H14NO2[M+H]+183.1125; Found:183.1122. See spectrum. Figures 1 to 3 .
[0059] The screening results for the above amino acid reduction-ring-opening reaction conditions are shown in Table 1 below.
[0060] Table 1: Screening Table for Amino Acid Reduction-Ring-Opening Reaction Conditions
[0061]
[0062]
[0063] Example 2
[0064] 13 C-C3-3,4-methylenedioxymethylamphetamine ( 13 C-C3-MDMA) preparation method.
[0065] 13C-C3-3,4-methylenedioxyphenylamphetamine (183 mg, 1 mmol) was dissolved in ethyl formate (10 mL) and heated to 100 °C for 2 hours. After cooling, the solvent was removed by rotary evaporation. The solution was then dissolved in 5 mL of diethyl ether and added dropwise to an ether suspension of lithium aluminum hydride (30 mg, 0.8 mmol). The mixture was heated to reflux for 5 hours, then cooled to 0 °C, and water was added dropwise. Insoluble matter was removed by diatomaceous earth filtration. The diatomaceous earth was washed with 10 mL of diethyl ether, and the organic phases were combined, washed with 5% sodium hydroxide aqueous solution, and dried over wastewater magnesium sulfate. The desiccant was removed by filtration, and the solvent was removed by rotary evaporation. The solution was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 4:1) to obtain... 13 C-C3-3,4-methylenedioxymethylamphetamine, colorless liquid (81 mg, 41%).
[0066] 1 H NMR(600MHz,cd3od)δ6.81–6.78(m,2H),6.74-6.70(m,1H),5.93(s,2H),3.54-3.50(m,0.5H),3.29-3.25(m,0.5H),3.18-3.10(m 0.5H),2.97-2.90(m,0.5H),2.84-2.77(m,0.5H),2.70(d,J=3.6Hz,3H),2.62 –2.54(m,0.5H),1.34(dt,J=6.6,4.4Hz,1.5H),1.12(dt,J=6.6,4.4Hz,1.5H).
[0067] 13 C NMR(151MHz,cd3od)δ149.66(d),148.46(s),130.54(d),123.71(t),110. 50(q),109.54(d),102.55(s),57.90(q),49.05(h),30.96(s),15.74(d).
[0068] HR-MS (ESI / TOF) m / z: Calcd. for C813C3H16NO2[M+H]+197.1282; Found: 197.1279. See spectrum. Figures 4 to 6 .
[0069] Example 3
[0070] by 13 C-C3-3,4-methylenedioxyamphetamine ( 13 C-C3-MDA) and 13 C-C3-3,4-methylenedioxymethylamphetamine ( 13C-C3-MDMA was used as an internal standard to detect the content of 3,4-methylenedioxyphenylamine and 3,4-methylenedioxymethylphenylamine in wastewater.
[0071] (1) Liquid chromatography-mass spectrometry detection conditions:
[0072] a) Instrument model: Shimadzu LCMS-8050;
[0073] b) Column: Allure PFPP 2.1 x 100 mm 5 μm;
[0074] c) Column temperature: 40℃;
[0075] d) Mobile phase: A: acetonitrile, B: water (0.1% formic acid), gradient: 0 min 5% A, 7 min 90% A, 9 min 90% A, 9.1 min 5% A, 11 min 5% A;
[0076] e) Flow rate: 0.4 mL / min;
[0077] f) Injection volume: 2 μL;
[0078] g) Ion source: Electrospray ion source, positive mode (ESI+);
[0079] h) Spray voltage 4000V;
[0080] i) Ion source temperature: 300℃;
[0081] j) Collision gas: Nitrogen.
[0082] The ion pairs and corresponding conditions are shown in Table 2:
[0083] Table 2
[0084]
[0085] (2) Sample pretreatment
[0086] Filter the wastewater sample through filter paper, take 100 mL, and add 2 mL of methanol (containing 10 ng / mL). 13 C-C3-MDA and 10 ng / ml 13 C-C3-MDMA was loaded onto an SPE column in 50 mL portions at a rate of 5 mL / min. After loading, the sample was first rinsed with 5 mL of methanol, and then eluted with 5 mL of 5% ammonia-acetonitrile solution. The eluent was evaporated to dryness under airflow in a 40°C water bath, redissolved with 80 μL of methanol, filtered through a 0.22 μL filter membrane, and 2 μL was injected into the LC-MS / MS for analysis.
[0087] (3) Plotting the standard curve
[0088] Add 50 μL of methanol (containing 50 ng / ml) to 50 mL of negative wastewater sample. 13 C-C3-MDA and 50ng / ml 13 Add 20 μL of MDA and MDMA standard references at concentrations of 1.25, 2.5, 5, 12.5, 25, and 250 ng / mL to prepare wastewater spiking samples at concentrations of 0.5, 1.0, 2.0, 5.0, 10, and 100 ng / L. Prepare three replicates for each concentration. Vortex for 3 min, allow to stand at room temperature for 30 min, and then process according to the sample pretreatment procedure before LC-MS / MS analysis. 13 A standard curve was plotted using the peak area ratio and concentration of C-C3-MDA to obtain the following results: Figure 7 The spectrum shown is given. The standard curve formula is Y = (0.0840196)X + (0.0247368), where X is the concentration of the sample to be tested, Y is the peak area obtained by liquid chromatography-mass spectrometry, b0 = 0.0247368 is the intercept of the standard curve, and b1 = 0.0840196 is the slope of the standard curve.
[0089] MDMA and 13 A standard curve was plotted using the peak area ratio and concentration of C-C3-MDMA, as shown below. Figure 8 The diagram shown. Figures 9 to 12 In sewage 13 C-C3-MDA, 13 Chromatograms of C-C3-MDMA, D5-MDA, and D5-MDMA samples were obtained. The standard curve formula is Y = (0.113621)X + (0.00654575), where X is the concentration of the sample to be tested, Y is the peak area obtained from liquid chromatography-mass spectrometry, b0 = 0.00654575 is the intercept of the standard curve, and b1 = 0.113621 is the slope of the standard curve.
[0090] Example 4
[0091] Comparison of the performance of carbon-13 markers and deuterated reference materials
[0092] Using the same detection conditions as in Example 3, urban domestic sewage samples under different pH and concentration conditions were tested. The results of retention time compliance rate and spiking recovery rate are compared as follows:
[0093] The formula for calculating the retention time compliance rate is:
[0094] F% = (t1-t0) / t0 * 100%
[0095] Where F% represents the retention time compliance rate, t1 represents the retention time of the internal standard, and t0 represents the retention time of the target analyte. A smaller F% value indicates that the chromatographic behavior of the internal standard is more similar to that of the target analyte, proving that it performs better as an internal standard. The results of the retention time compliance rate comparison are shown in Table 3.
[0096] Table 3 Comparison of Retention Time Compliance Rate
[0097] target internal standard Retention time compliance rate MDA <![CDATA[ 13 C-C3-MDA]]> 0.05% MDA D4-MDA 0.70% MDMA <![CDATA[ 13 C-C3-MDMA]]> 0.05% MDMA D4-MDMA 0.73%
[0098] The formula for calculating the recovery rate is as follows:
[0099] E% = (AB) / C * 100%
[0100] In the table, A represents the detection result after spiking, B represents the detection result before spiking, C represents the spiking amount, and E% represents the spiking recovery rate. The closer the E% value is to 100%, the more accurate the results of the detection system are, indicating that the internal standard has better performance. The spiking recovery rates of different internal standards under different conditions are shown in Table 4.
[0101] Table 4. Results of detection using different internal standards under different conditions: recovery rate
[0102]
[0103]
[0104] Acidic wastewater, alkaline wastewater, oxidizing wastewater, and reducing wastewater: The substrate is made by adding domestic sewage. The acidic solution is adjusted to pH=2 with hydrochloric acid, the strongly alkaline solution is adjusted to pH=12 with sodium hydroxide, the oxidizing solution is made with 0.1mol / L sodium hypochlorite and peracetic acid, and the reducing solution is made with 0.1mol / L sodium sulfite.
[0105] The isotope-labeled internal standard provided by this invention, when detecting the psychoactive substance MDMA in samples, can be used by adding an appropriate amount of this [method / material] to the sample. 13 C-C3-MDMA was pretreated appropriately according to the detection requirements before being detected by liquid chromatography-mass spectrometry (LC-MS / MS). 13 C-C3-MDMA serves as an internal standard. In multiple reaction monitoring (MRM) mode, it enables qualitative and quantitative detection of the analyte by comparing the peak area ratio of the target substance and the analyte. It can detect MDMA as a psychoactive substance with high specificity and sensitivity.
[0106] In this specification, the invention has been described with reference to specific embodiments thereof. However, it will be apparent that various modifications and variations can be made without departing from the spirit and scope of the invention. Therefore, this specification should be considered illustrative rather than restrictive.
Claims
1. A carbon-13 isotope-labeled internal standard for MDMA and its metabolites, characterized in that, The chemical structural formula of the internal standard is shown below: Where R is H or methyl.
2. A method for preparing an MDA carbon-13 isotope-labeled internal standard, characterized in that, The preparation method includes the following steps: (1) 13 C-C3-alanine is generated under transition metal catalysis. 13 C-C3-azacyclopropane; (2) 13 C-C3-azacyclopropane reacts with a 3,4-methylenedioxyphenyl nucleophile to generate a carbon-13 isotopically labeled internal standard for MDA. 13 C-C3-3,4-methylenedioxyphenylamine.
3. The method for preparing the MDA carbon-13 isotope-labeled internal standard according to claim 2, characterized in that, In step (1), the transition metal catalyst is Ir(acac)(CO)2; In step (2), the reaction catalyst is CuBr or CuI; the reaction is stirred at temperature t2 for 2 hours, and then heated to room temperature t3 for 2 hours. t2 is -35℃ to 25℃, t3 is 0℃ to 25℃, and T2 is 1 to 4 hours.
4. A method for preparing an MDMA carbon-13 isotope-labeled internal standard, characterized in that, The preparation method includes the following steps: Internal standard labeled with MDA carbon-13 isotope 13 C-C3-3,4-methylenedioxyphenylamine is methylated to generate an MDMA carbon-13 isotope-labeled internal standard. 13 C-C3-3,4-Methylenedioxymethylamphetamine, MDA carbon-13 isotope labeled internal standard 13 C-C3-3,4-methylenedioxyphenylpropanol is prepared by the method described in claim 2 or 3.
5. The use of the carbon-13 isotope-labeled internal standard of MDMA and its metabolites as described in claim 1, or the carbon-13 isotope-labeled internal standard of MDA prepared by the preparation method described in claims 2-3, for detecting the MDA content in wastewater.
6. The use of the carbon-13 isotope-labeled internal standard of MDMA and its metabolites as described in claim 1, or the carbon-13 isotope-labeled internal standard of MDMA prepared by the preparation method described in claim 4, for detecting the MDMA content in wastewater.
